Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) – Drugs in Development, 2021

According to the recently published report 'Hepcidin – Drugs in Development, 2021'; Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) pipeline Target constitutes close to 5 molecules.

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) – Hepcidin is a protein encoded by the HAMP gene. It acts by promoting endocytosis and degradation of ferroportin leading to the retention of iron in iron exporting cells and decreased flow of iron into plasma. It controls the major flows of iron into plasma, absorption of dietary iron in the intestine and recycling of iron by macrophages.

The report 'Hepcidin – Drugs in Development, 2021' outlays comprehensive information on the Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 4 respectively. Report covers products from therapy areas Immunology, Genetic Disorders, Hematological Disorders, Oncology and Undisclosed which include indications Acute Inflammation, Anemia, Hemochromatosis, Polycythemia Vera and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)

– The report reviews Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics and enlists all their major and minor projects

– The report assesses Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Daiichi Sankyo Co Ltd

Protagonist Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Overview

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Companies Involved in Therapeutics Development

Daiichi Sankyo Co Ltd

Protagonist Therapeutics Inc

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drug Profiles

DS-28120313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-42450411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-79182026 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTG-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Dormant Products

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Discontinued Products

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Product Development Milestones

Featured News & Press Releases

Mar 22, 2021: Protagonist announces plans to initiate a global phase 3 study for Rusfertide in polycythemia vera following interactions with the U.S. Food & Drug Administration and the European Medicines Agency

Dec 07, 2020: Protagonist announces results of large-scale analysis of current treatment patterns revealing significant opportunity to improve the standard of care for patients with polycythemia vera across Broad population categories

Dec 06, 2020: Protagonist announces updated phase 2 data presented at ASH Annual Meeting supporting long term efficacy of hepcidin mimetic PTG-300 in the treatment of Polycythemia Vera

Dec 02, 2020: Protagonist's Hepcidin Mimetic candidate PTG-300 receives Fast Track Designation from the U.S. Food and Drug Administration for development in the treatment of polycythemia vera

Nov 04, 2020: Protagonist Therapeutics to present updated clinical data for hepcidin mimetic PTG-300 in polycythemia vera at the American Society for Hematology (ASH) 2020 Annual Meeting

Oct 21, 2020: Protagonist Therapeutics receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera

Sep 02, 2020: Protagonist Therapeutics to host PTG-300 opportunity update webinar

Jun 17, 2020: Hepcidin Mimetic PTG-300 receives U.S. FDA Orphan Drug Designation for the treatment of Polycythemia Vera

Jun 04, 2020: Protagonist Therapeutics to present at the 25th European Hematology Association (EHA) Annual Congress

May 07, 2020: Protagonist Therapeutics announces initial phase 2 results with hepcidin mimetic PTG-300 in the treatment of Polycythemia Vera

Jan 07, 2020: Protagonist Therapeutics initiates phase 2 study of novel Hepcidin Mimetic PTG-300 in the treatment of patients with Hereditary Hemochromatosis

Dec 03, 2019: Protagonist Therapeutics announces preliminary phase 2 results with hepcidin mimetic PTG-300 in the treatment of transfusion dependent beta-Thalassemia

Oct 31, 2019: Protagonist doses first patient in Phase II study of PTG-300

Jan 09, 2019: Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia

Sep 27, 2018: Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Daiichi Sankyo Co Ltd, 2021

Pipeline by Protagonist Therapeutics Inc, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports